Foghorn Therapeutics (FHTX) Net Margin (2020 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Net Margin came in at 2468.38% in Q1 2026, down 208224.0% year-on-year from N/an in Q1 2025, and down 857.07% quarter-over-quarter from 257.91% in Q4 2025.
Foghorn Therapeutics (FHTX) Net Margin (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Net Margin history runs 7 years deep, the most recent figure standing at 2468.38% for Q1 2026.
- On a quarterly basis, Net Margin fell 208224.0% year-over-year to 2468.38% in Q1 2026; TTM through Mar 2026 was 800.84%, a 44096.0% decrease from a year earlier, with the FY2025 full-year figure at 858.26%, down 47502.0% from the prior year.
- Net Margin declined to 2468.38% in Q1 2026 per FHTX's latest filing, from 257.91% in the prior quarter.
- Across five years, Net Margin topped out at 82.07% in Q3 2023 and bottomed at 2468.38% in Q1 2026.
- The 5-year median for Net Margin is 512.09% (2025), against an average of 612.45%.
- Across the five-year window, Net Margin jumped 24430424 bps in 2022 and plunged 208224 bps in 2026, its largest moves.
- Year by year, Net Margin stood at 690.39% in 2022, then jumped by 39 bps to 417.85% in 2023, then plunged by 63 bps to 682.88% in 2024, then surged by 62 bps to 257.91% in 2025, then slumped by 857 bps to 2468.38% in 2026.
- Per Business Quant, the three latest FHTX Net Margin figures stand at 2468.38% (Q1 2026), 257.91% (Q4 2025), and 512.09% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - | -2,468.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,468.38% |
| Dec 31, 2025 | -257.91% |
| Sep 30, 2025 | -512.09% |
| Jun 30, 2025 | -1,055.82% |
| Mar 31, 2025 | -386.14% |
| Dec 31, 2024 | -682.88% |
| Sep 30, 2024 | -244.90% |
| Jun 30, 2024 | -333.61% |
| Mar 31, 2024 | -495.37% |
| Dec 31, 2023 | -417.85% |
| Sep 30, 2023 | -82.07% |
| Jun 30, 2023 | -526.65% |
| Mar 31, 2023 | -574.27% |
| Dec 31, 2022 | -690.39% |
| Sep 30, 2022 | -388.44% |
| Jun 30, 2022 | -608.31% |
| Mar 31, 2022 | -686.58% |
| Dec 31, 2021 | -5,133.38% |
| Sep 30, 2021 | -244,692.68% |
| Jun 30, 2021 | -35,768.46% |